^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | EDIT-202 (NK cell stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing
Published date:
05/03/2022
Excerpt:
EDIT-202 induced significantly enhanced anti-tumor efficacy in vivo when evaluated using a SKOV3 HER2+ ovarian cancer model.
